RSSDI Repository, Complications of Diabetes Demonstration
RSSDI Repository, Complications of Diabetes Demonstration

Have a Question?

If you have any question you can ask below or enter what you are looking for!

Advanced Search
  • Home/
  • Article /
  • … and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes …

… and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes …

Add to Collection
RCTs VA Fonseca, R Alvarado-Ruiz, D Raccah… - Diabetes …, 2012 - Am Diabetes Assoc

Chapter : Section2, Section9
Journal Year : 2012
Cited by : 265

… Rates of symptomatic hypoglycemia associated with lixisenatide in the current study were … , but has the advantages of less hypoglycemia and fewer gastrointestinal adverse events (18). …..... Read More

Keywords : ['randomize doubleblind placebocontrolle trial', 'oncedaily receptor agonist lixisenatide', 'type diabetes', 'safety', 'patient', 'monotherapy']
PubMed Link : https://diabetesjournals.org/care/article-abstract/35/6/1225/38983
Google Scholar Link : https://scholar.google.com/scholar?cites=5291869053556742629&as_sdt=80000005&sciodt=0,23&hl=en&num=20